Deal title |
Principal company |
Partner company |
Total projected at signing (US$M) |
Most recent event date |
FEBRUARY | ||||
Albany Molecular Research to provide cGMP manufacturing and analytical support for a complex parenteral drug product |
Albany Molecular Research Inc. |
Ferrer Internacional SA |
Payment |
2/21/17 |
Acbel to distribute Antibe's ATB-346 for gastrointestinal ulcer and bleeding associated with NSAIDs in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan |
Antibe Therapeutics Inc. |
Laboratories Acbel SA |
$1.10 |
2/24/17 |
Tersera to commercilaize Astrazeneca's Zoladex in the U.S. and Canada |
Astrazeneca plc |
Tersera Therapeutics |
$320.00 |
2/20/17 |
Chinese Peptide and Zhejiang Haiding Pharmaceutical to develop HDP-111001 against undisclosed indication |
Chinese Peptide Co. |
Zhejiang Haiding Pharmaceutical Co. Ltd. |
Unknown |
2/22/17 |
Serum Institute of India to market Cipla's hepatitis B vaccine in India |
Cipla Ltd. |
Serum Institute of India Ltd. |
Payment |
2/17/17 |
ANI acquires Holmdel's Innopran XL against hypertension |
Holmdel Pharmaceuticals LP |
ANI Pharmaceuticals Inc. |
$31.00 |
2/23/17 |
Inmed and Revive to sign term sheet on discovery and development of cannabinoid therapies for kidney diseases worldwide |
Inmed Pharmaceuticals Inc. |
Revive Therapeutics Ltd. |
Payment |
2/22/17 |
Global pharmaceutical company to license Isogenica's llamdA VHH single-domain antibody libraries for the development and commercialization of therapeutic products |
Isogenica Ltd. |
Undisclosed |
Payment |
2/21/17 |
Biosense to opt to develop and commercialize Neovacs' IFN alpha kinoid vaccine for lupus and dermatomyositis in China and other selected territories |
Neovacs SA |
Biosense Global LLC |
$69.01 |
2/21/17 |
Novozymes and Defensin Therapeutics to develop recombinant human beta-defensin-2 against colitis |
Novozymes A/S |
Defensin Therapeutics ApS |
Payment |
2/17/17 |
Finch Therapeutics to license Openbiome's stool banking technology to develop Finch's FIN-403 for recurrent clostridium difficile infection |
Openbiome |
Finch Therapeutics |
Payment |
2/23/17 |
Xynomic Pharmaceuticals to develop and commercialize Pharmacyclics' Abexinostat against cancer worldwide |
Pharmacyclics Inc. |
Xynomic Pharmaceuticals |
Payment |
2/24/17 |
4P Pharma and Pulsalys to codevelop for the development of Onco-Bcl program against cancer with sublicensing option |
Pulsalys Inc. |
4P Pharma |
Payment |
2/28/17 |
Sanofi and Lonza to form joint venture for monoclonal antibody production |
Sanofi SA |
Lonza Group AG |
Unknown |
2/27/17 |
Selexis to develop cell lines using SUREtechnology platform for three Sanofi biologics programs in cancer and infectious disease |
Selexis SA |
Sanofi SA |
Payment |
2/21/17 |
Santen and Twoxar to discover new glaucoma candidates using computational drug discovery platform |
Twoxar Inc. |
Santen Inc. |
Payment |
2/23/17 |
Sobi to distribute Valeant's Ammonul for urea cycle disorders in Europe, the Middle East and North Africa |
Valeant Pharmaceuticals International Inc. |
Swedish Orphan Biovitrum AB |
Payment |
2/21/17 |
Phytecs and Yissum Research to discover endocannabinoid system targeting compounds and to test fluorinated cannabidiol |
Yissum Research Development Co. |
Phytecs Inc. |
Payment |
2/22/17 |
Leukocare to provide patented SPS formulation technologies access to Rentschler Biotechnologie |
Dr Rentschler Biotechnologie GmbH |
Leukocare AG |
Payment |
2/2/17 |
Edelris to use Keymical Space for identification of lead molecules against Pfizer selected targets |
Edelris SAS |
Pfizer Inc. |
Payment |
1/31/17 |
Amag Pharmaceuticals to develop and commercialize Endoceutics' prasterone against dyspareunia, vulva and vaginal atrophy in the U.S. |
Endoceutics Inc. |
Amag Pharmaceuticals Inc. |
$965 |
2/13/17 |
Agro-Tek to distribute Engen's Munchies B Gone gum to counteract biological cause of cannabis induced hunger in Canada |
Engen Medical Corp. |
Agro-Tek Inc. |
Payment |
2/6/17 |
MARCH | ||||
Ajinomoto Althea to provide technology transfer, validation and commercial fill/finish services to Revance's daxibotulinumtoxin A |
Ajinomoto Althea Inc. |
Revance Therapeutics Inc. |
Payment |
3/14/17 |
Brill Pharma to distribute Alimera's Iluvien for diabetic macular edema in Spain |
Alimera Sciences Inc. |
Brill Pharma SL |
Payment |
3/13/17 |
Horizon Discovery to evaluate impact of Amplycell's BOOST cell line optimization technology on Horizon's parental GS null CHO K1 cell line worldwide |
Amplycell SA |
Horizon Discovery Group plc |
Payment |
3/8/17 |
Angsana Molecular & Diagnostics and Ignyta to conduct a STARTRK-2 clinical trial for entrectinib in Asia |
Angsana Molecular & Diagnostics Laboratory Pte. Ltd. |
Ignyta Inc. |
Payment |
3/3/17 |
DKSH to distribute APR Applied Pharma Research's diclofenac 50 mg powder for migraine and pain in Asia |
APR Applied Pharma Research SA |
DKSH Holding Ltd. |
Payment |
3/6/17 |
Ferring acquires Apricus Biosciences' Vitaros assets outside the U.S. |
Apricus Biosciences Inc. |
Ferring Pharmaceuticals SA |
$13.30 |
3/8/17 |
Alexion to use Arbutus' LNP delivery technology in its single messenger RNA product candidate for rare disease programs |
Arbutus Biopharma Corp. |
Alexion Pharmaceuticals Inc. |
$82.50 |
3/16/17 |
Argen-X and Staten Biotech to develop ARGX-116 through its Innovative Access Program against dyslipidemia |
Argen-X NV |
Staten Biotechnology BV |
Payment |
3/6/17 |
Argen-X and Broteio Pharma to develop therapeutic complement-targeted antibody against autoimmune hemolytic anemia and antibody mediated rejection, with an option |
Argen-X NV |
Broteio Pharma BV |
Payment |
3/21/17 |
Circassia to commercialize Astrazeneca's Tudorza and Duaklir for various chronic obstructive pulmonary disease in U.S. |
Astrazeneca plc |
Circassia Pharmaceuticals plc |
$292.50 |
3/17/17 |
Biomerieux to develop and market Astute's Nephrocheck test for Vidas, an assay to assess the risk of developing acute kidney injury worldwide |
Astute Medical Inc. |
Biomerieux SA |
Unknown |
3/13/17 |
Roche to supply Tecentriq to evaluate Bavarian's CV-301 and Tecentriq in bladder cancer |
Bavarian Nordic A/S |
Roche Holding AG |
Payment |
3/10/17 |
Beigene and GET to establish joint venture to provide funding for research and development of biologic drug candidates in China |
Beigene Co. Ltd. |
Guangzhou GET Technology Development Co. Ltd. |
Unknown |
3/7/17 |
Bergenbio and Merck to conduct phase II clinical studies on BGB-324 in combination with Keytruda against non-small-cell lung cancer and triple-negative breast cancer |
Bergenbio AS |
Merck & Co. Inc. |
Payment |
3/8/17 |
Catalyst to use Biocept's target selector platform for LEMS patients in phase III Firdapse trial |
Biocept Inc. |
Catalyst Pharmaceutical Partners Inc. |
Payment |
3/14/17 |
MediLoc Laborsysteme to distribute Biolog's product lines in Germany and Austria |
Biolog Inc. |
Mediloc Laborsysteme GmbH |
Payment |
3/6/17 |
Mill Creek to distribute Biological Industries' PLTMax Human Platelet Lysate |
Biological Industries Co. Ltd. |
Mill Creek Life Sciences |
Payment |
3/6/17 |
Biologics to provide specialty pharmacy services for Novartis' ribociclib against HR+/HER2- advanced breast cancer |
Biologics Inc. |
Novartis AG |
Payment |
3/17/17 |
Bioversys and Aptuit to identify and validate new targets and molecules for Gram-negative bacteria |
Bioversys AG |
Aptuit LLC |
Payment |
3/7/17 |
Nemus Bioscience to use Catalent's softgel technology for delivery of NB-1222 against chemotherapy-induced nausea and vomiting |
Catalent Inc. |
Nemus Bioscience Inc. |
Payment |
3/3/17 |
Bluelink Pharmaceuticals acquires Cerulean Pharma's CRLX-101 and CRLX-301 for cancer |
Cerulean Pharma Inc. |
Bluelink Pharmaceuticals |
$1.50 |
3/19/17 |
Provecs to use Cevec's CAPGT technology to develop adenoviral gene therapy vectors for cancer |
Cevec Pharmaceuticals GmbH |
Provecs Medical GmbH |
Payment |
3/16/17 |
Medac to use Cevec's CAPGT technology to develop adenoviral gene therapy vectors for cancer |
Cevec Pharmaceuticals GmbH |
Medac GmbH |
Payment |
3/16/17 |
Oxford Genetics to distribute CLS Cell Lines Service's cell lines worldwide |
CLS Cell Lines Service GmbH |
Oxford Genetics Ltd. |
Payment |
3/6/17 |
Vertex Pharmaceuticals to acquire Concert's CTP-656 against cystic fibrosis |
Concert Pharmaceuticals Inc. |
Vertex Pharmaceuticals Inc. |
$250.00 |
3/3/17 |
Neogenomics and Definiens to develop new biomarker assays for clinical trials and clinical testing |
Definiens AG |
Neogenomics Inc. |
Unknown |
3/13/17 |
Diplomat to distribute Lexicon Pharmaceuticals' telotristat against carcinoid syndrome diarrhea |
Diplomat Pharmacy Inc. |
Lexicon Pharmaceuticals Inc. |
Payment |
3/6/17 |
China Medical System to commercialize Dr Falk's mesalazine for ulcerative colitis and Crohn's disease in People's Republic of China |
Dr. Falk Pharma GmbH |
China Medical System Holdings Ltd. |
Payment |
3/16/17 |
Sandoz to license DSM's IP assets for the manufacture of beta lactam antibiotics worldwide |
DSM Sinochem Pharmaceuticals Ltd. |
Sandoz Pharmaceuticals Corp. |
Payment |
3/17/17 |
Duchesnay to develop and commercialize Shionogi's Osphena against dyspareunia in the U.S. and Canada |
Duchesnay Inc. |
Shionogi Inc. |
Payment |
3/10/17 |
Allergan to license Editas' 5 genome editing programs including LCA-10 for ocular diseases |
Editas Medicine Inc. |
Allergan plc |
$90.00 |
3/14/17 |
Oncbiomune to sign a non-binding term sheet to form a joint venture to develop and commercialize EOC Pharma's products including telatinib in 34 countries of MALA |
EOC Pharma Ltd. |
Oncbiomune Pharmaceuticals Inc. |
Unknown |
3/14/17 |
Fuji Yakuhin and Mochida Pharmaceutical to develop FYU-981 against hyperuricemia |
Fuji Yakuhin Co. Ltd. |
Mochida Pharmaceutical Co. Ltd. |
Payment |
3/6/17 |
AGT to conduct phase I clinical studies by combining lentiviral vector technology with Geovax's MVA-VLP HIV vaccine against HIV infection |
Geovax Labs Inc. |
American Gene Technologies International Inc. |
Payment |
3/14/17 |
Guangzhou Ruibeisi and Guangzhou Yinheyangguang to investigate a lyophilized, inactived human rabies vaccine produced from Vero cells |
Guangzhou Ruibeisi Pharmaceutical Co. Ltd. |
Guangzhou Yinheyangguang Biological Products Co. Ltd. |
Payment |
3/6/17 |
Daiichi Sankyo to develop Heptares' small molecule against G-protein coupled receptors for pain |
Heptares Therapeutics Ltd. |
Daiichi Sankyo Co. Ltd. |
$4.00 |
3/13/17 |
Pierre Fabre to distribute Hill Dermaceuticals' Tolak for actinic keratosis in the U.S. and other territories |
Hill Dermaceuticals Inc. |
Pierre Fabre Dermo-Cosmetique |
Payment |
3/6/17 |
Pierre Fabre to develop fully human monoclonal antibodies for cancer using H-Immune's IVI technology |
H-Immune SAS |
Pierre Fabre SA |
Payment |
3/21/17 |
Immune Therapeutics and Omaera to sign a memorandum of understanding for distribution of Lodonal for HIV infection and immune disorders in Kenya |
Immune Therapeutics Inc. |
Omaera Pharmaceuticals |
Payment |
3/8/17 |
Key Capital to distribute Immunitor's immunotherapy products for cancer in Latin America |
Immunitor Inc. |
Key Capital Corp. |
Payment |
3/7/17 |
Integral Molecular and Integrated Biotherapeutics to discover and develop virus vaccines against Ebola and Zika virus infection |
Integrated Biotherapeutics Inc. |
Integral Molecular Inc. |
Payment |
3/2/17 |
Illumina to comarket Kailos' Targetrich PGxComplete and Kailos Blue research solutions for pharmacogenetics targets |
Kailos Genetics Inc. |
Illumina Inc. |
Payment |
3/21/17 |
Kuhnil to distribute Kitov's KIT-302 for pain and hypertension in South Korea |
Kitov Pharmaceuticals Ltd. |
Kuhnil Pharmaceutical Co. Ltd. |
Payment |
3/8/17 |
Arix Bioscience and Lead Discovery Center to develop therapeutics for metabolic diseases |
Lead Discovery Center GmbH |
Arix Bioscience plc |
Payment |
3/20/17 |
Loxo Oncology and Ventana Medical Systems to develop and commercialize pan-TRK IHC companion diagnostic test to identify tumor types for larotrectinib treatment |
Loxo Oncology Inc. |
Ventana Medical Systems Inc. |
Payment |
3/20/17 |
Amring acquires six ANDAs including niche otic and ophthalmic pharmaceuticals from Luitpold Pharmaceuticals and Alphaforce |
Luitpold Pharmaceuticals Inc. |
Amring Pharmaceuticals |
Payment |
3/1/17 |
PTC Therapeutics to acquire Marathon Pharmaceuticals' Emflaza against Duchenne muscular dystrophy |
Marathon Pharmaceuticals LLC |
PTC Therapeutics Inc. |
$190.00 |
3/15/17 |
Kissei and Maruishi to develop and commercialize MR-13A9 for uremic pruritus in Japan |
Maruishi Pharmaceutical Co. Ltd. |
Kissei Pharmaceutical Co. Ltd. |
Payment |
3/13/17 |
Crispr Therapeutics to use Maxcyte's cell engineering platform to develop CRISPR/Cas9-based therapies for hemoglobin diseases and severe-combined immunodeficiency |
Maxcyte Inc. |
Crispr Therapeutics |
Payment |
3/14/17 |
Sanofi Pasteur and Medimmune to develop and commercialize MEDI-8897 against respiratory syncytial virus |
Medimmune LLC |
Sanofi Pasteur Inc. |
$647.29 |
3/3/17 |
Menarini to develop and commercialize Melinta's delafloxacin against bacterial infections in various countries |
Melinta Therapeutics Inc. |
The Menarini Group |
Payment |
3/2/17 |
Mercachem to provide Aicuris lead optimization services for multiple anti-infective targets |
Mercachem Holding BV |
Aicuris Anti-infective Cures GmbH |
Payment |
3/8/17 |
Fuji Pharma to enter into a letter of intent with Mithra to develop and commercialize Donesta in Japan and ASEAN |
Mithra Pharmaceuticals |
Fuji Pharma Co. Ltd. |
Payment |
3/1/17 |
Bio-Techne to license reagents and media systems from Multiclonal Therapeutics for ground state stem cell technology |
Multiclonal Therapeutics Inc. |
Bio-Techne Corp. |
Payment |
3/7/17 |
Nemus to use Nanomerics' MET to develop topical ocular formulation of NB-1111 for glaucoma |
Nanomerics Ltd. |
Nemus Bioscience Inc. |
Payment |
3/20/17 |
Neos Therapeutics to license patents rights related to NT-0201 from Shire against attention deficit hyperactivity disorder |
Neos Therapeutics Inc. |
Shire plc |
$1.00 |
3/6/17 |
Trovagene to develop and commercialize Nerviano's PCM-075 for acute myeloid leukemia worldwide |
Nerviano Medical Sciences Srl |
Trovagene Inc. |
$2.00 |
3/15/17 |
Biocodex to commercialize Neurim's PedPRM for children with sleep disorders in France |
Neurim Pharmaceuticals |
Laboratoires Biocodex |
Payment |
3/13/17 |
Servier to develop Neurochlore's bumetanide for autism in Europe |
Neurochlore |
Servier |
Payment |
3/14/17 |
Nlife and Wave to develop cell-specific targeting of nucleic acid therapeutics for central nervous system genetic diseases |
Nlife Therapeutics SL |
Wave Life Sciences Ltd. |
Payment |
3/3/17 |
Novalix to provide on-site discovery chemistry services for small molecules drug discovery programs for UCB Biopharma |
Novalix |
UCB Biopharma SPRL |
Payment |
3/7/17 |
4d Pharma to use Owlstone Medical's biomarker services to discover novel non-invasive biomarkers |
Owlstone Medical Ltd. |
4d Pharma plc |
Payment |
3/7/17 |
Mayne to distribute Par Pharmaceutical's fentanyl TDS against pain in the U.S. |
Par Pharmaceutical Inc. |
Mayne Pharma Group Ltd. |
Payment |
3/9/17 |
Breath Therapeutics to license Pari Pharma's ciclosporin against bronchiolitis obliterans syndrome |
Pari Pharma GmbH |
Breath Therapeutics Holding BV |
Payment |
3/20/17 |
Galapagos and Pharnext to develop new synergistic drug combinations for various indications |
Pharnext SAS |
Galapagos NV |
Payment |
3/9/17 |
Poplar Healthcare to offer Roche's cobas HPV test for cervical cancer screening and the cobas EGFR mutation test for non-small-cell lung cancer |
Poplar Healthcare |
Roche Holding AG |
Payment |
3/13/17 |
Quintiles to provide development services for Verona's RPL-554 in chronic obstructive pulmonary disease and cystic fibrosis treatment |
Quintiles Transnational Corp. |
Verona Pharma plc |
Payment |
3/22/17 |
AMO Pharma and Ranedis to develop RND-001 for various neurological disorders |
Ranedis Pharmaceuticals |
AMO Pharma Ltd. |
Payment |
3/14/17 |
R-Health and Bioverativ to conduct research on a coagulation assay using its Rhealth diagnostic platform |
R-Health LLC |
Bioverativ Inc. |
Payment |
3/7/17 |
Rubicon and Syngene to develop another application of ARX-050, modified Annexin's ability to target additional tumor cell lines |
Rubicon Biotechnology Inc. |
Syngene International Ltd. |
Payment |
3/9/17 |
Sacco to manufacture and supply Optibiotix's cholesterol reducing strain, LPLDL, in Europe |
Sacco Srl |
Optibiotix Health plc |
Payment |
3/8/17 |
Chugai to commercialize SBI Pharma's Alaglio for bladder cancer in Japan |
SBI Pharmaceuticals |
Chugai Pharmaceutical Co. Ltd. |
Payment |
3/13/17 |
Scohia Pharma to license eight research and development projects from Takeda including TAK-272, TAK-792 and TAK-094 |
Takeda Pharmaceutical Co. Ltd. |
Scohia Pharma Inc. |
Payment |
3/14/17 |
Oncbiomune to sign term sheet to acquire Teva Pharmaceuticals' norepinefrine generic in Mexico |
Teva Pharmaceutical Industries Ltd. |
Oncbiomune Pharmaceuticals Inc. |
Payment |
3/20/17 |
Maruho to develop and commercialize Toray's ROR gamma t inhibitor for autoimmune diseases worldwide |
Toray Industries Inc. |
Maruho Co. Ltd. |
Payment |
3/14/17 |
Aequus to enter a binding term sheet to license TRPL's transdermal patch against epilepsy, multiple sclerosis and other neurological disorders worldwide |
Transdermal Research Pharm Laboratories LLC |
Aequus Pharmaceuticals Inc. |
Payment |
3/2/17 |
Upsher-Smith to market and distribute undisclosed pharmaceutical company's generic products in the U.S. |
Undisclosed |
Upsher-Smith Laboratories Inc. |
Payment |
3/17/17 |
Valeant to develop and commercialize Glycyx's methylnaltrexone bromide containing products for oncology indications outside the U.S. and Canada |
Valeant Pharmaceuticals International Inc. |
Glycyx Pharmaventures Ltd. |
Payment |
3/15/17 |
Vedantra and Neon Therapeutics to develop cancer vaccines |
Vedantra Pharmaceuticals Inc. |
Neon Therapeutics |
Payment |
3/14/17 |
Namaste Technologies to sign a memorandum of understanding to commercialize Vinergy's cannabidiol extract formulations in the U.S. |
Vinergy Resources Ltd. |
Namaste Technologies Inc. |
Payment |
3/14/17 |
X-Chem to discover novel compounds for Astellas' targets against multiple therapeutic areas |
X-Chem Inc. |
Astellas Pharma Inc. |
$116.00 |
3/20/17 |
Ono to use X-Chem's DEX platform for small molecules discovery against oncology targets worldwide |
X-Chem Inc. |
Ono Pharmaceutical Co. Ltd. |
Payment |
3/21/17 |
Kadimastem to license Yeda's patent related to the method of producing supporting cells in the central nervous system from stem cells |
Yeda Research and Development Co. Ltd. |
Kadimastem Ltd. |
Payment |
3/16/17 |
ZS Genetics and Hitachi High Technologies to develop and commercialize ZS Genetics' DNA sequencing platform |
ZS Genetics Inc. |
Hitachi High Technologies America Inc. |
Payment |
3/8/17 |
Jiangsu Nhwa to commercialize Zysis' aripiprazole for psychotic disorders in China |
Zysis Ltd. |
Jiangsu Nhwa Pharmaceutical Group Co. Ltd. |
$0.70 |
3/13/17 |
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Thomson Reuters Cortellis. |